NCT06036784 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

November 14, 2024

Study Completion Date

December 5, 2024

Conditions

Postbariatric Hypoglycemia

Interventions

DRUG

MBX 1416 (Part A)

Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg

DRUG

MBX 1416 (Part B)

Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg

DRUG

Placebo

Single dose or repeated subcutaneous (SC) dose of placebo.

DRUG

MBX 1416 (Part C)

Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.

Trial Locations (1)

91911

MBX Biosciences Investigational Site, Chula Vista